StockData

Assembly Biosciences vs Gossamer Bio

ASMB and GOSS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ASMB and GOSS compare

Gossamer Bio is the larger company, worth 12 times as much as Assembly Biosciences ($5.4B against $433M).

Assembly Biosciences grew revenue faster over the last twelve months (125% versus 32.4% for Gossamer Bio).

Assembly Biosciences keeps more of each dollar of sales as profit, with a net margin of −0.06% compared with −235% at Gossamer Bio.

Assembly Biosciences scores higher on the StockData Score (12 against 1 for Gossamer Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricASMBGOSS
Size and price
Market cap$433M$5.4B
Share price$21.29$10.98
Change, 1 year−40.1%−94.5%
Change, 5 years−24.5%−98.7%
Beta (5Y)1.012.34
Employees73161
StockData Score
Total score12 (better)1
Valuation score2 (better)0
Growth score11
Performance score3 (better)0
Health score6 (better)0
Dividend score00
Valuation
P/S5.8× (better)101×
P/B1.4×–
FCF yield−8.9%−3.0% (better)
Fair value$24.73–
Margin of safety13.9%–
Growth
Revenue growth (TTM)125% (better)32.4%
Revenue growth, 5Y average−1.8%–
Profitability
Operating margin−11.8% (better)−312%
Net margin−0.06% (better)−235%
FCF margin−51.5% (better)−305%
Return on equity−0.03%–
Financial health
Debt / equity0.00–
Interest coverage–−15.2×
Current ratio13.99 (better)0.53
Altman Z-score8.00 (better)−15.36
Piotroski F-score4 (better)1
Dividends and buybacks
Buyback yield0.00%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions92.1%0.98%
Held by insiders29.3%2.8%
Insider net buying, 12 months−$252K–
Superinvestors holding–1
Short interest, % of float21.1%0.28%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.